Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers  by Haque, Farzin et al.
Nano Today (2012) 7, 245—257
Available online at www.sciencedirect.com
journa l homepage: www.e lsev ier .com/ locate /nanotoday
RAPID COMMUNICATION
Ultrastable synergistic tetravalent RNA nanoparticles
for targeting to cancers
Farzin Haquea,c,1, Dan Shua,c,1, Yi Shua,c,1, Luda S. Shlyakhtenkod,
Piotr G. Rychahoub, B. Mark Eversb, Peixuan Guoa,b,c,∗
a Nanobiotechnology Center, College of Pharmacy, University of Kentucky, Lexington, KY 40536, United States
b Markey Cancer Center, College of Pharmacy, University of Kentucky, Lexington, KY 40536, United States
c Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, United States
d Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, United States
Received 12 April 2012; received in revised form 14 June 2012; accepted 25 June 2012
KEYWORDS
Nanotechnology;
Nanobiotechnology;
Nanomotor;
DNA packaging
motor;
Bacteriophage phi29;
RNA nanotechnology;
RNA nanoparticle;
RNA therapeutics
Summary One of the advantages of nanotechnology is the feasibility to construct therapeutic
particles carrying multiple therapeutics with deﬁned structure and stoichiometry. The ﬁeld of
RNA nanotechnology is emerging. However, controlled assembly of stable RNA nanoparticles
with multiple functionalities which retain their original role is challenging due to refolding
after fusion. Herein, we report the construction of thermodynamically stable X-shaped RNA
nanoparticles to carry four therapeutic RNA motifs by self-assembly of reengineered small
RNA fragments. We proved that each arm of the four helices in the X-motif can harbor one
siRNA, ribozyme, or aptamer without affecting the folding of the central pRNA-X core, and
each daughter RNA molecule within the nanoparticle folds into their respective authentic
structures and retains their biological and structural function independently. Gene silencing
effects were progressively enhanced as the number of the siRNA in each pRNA-X nanoparticles
gradually increased from one to two, three, and four. More importantly, systemic injection of
ligand-containing nanoparticles into the tail-vein of mice revealed that the RNA nanoparticles
remained intact and strongly bound to cancers without entering the liver, lung or any other
organs or tissues, while remaining in cancer tissue for more than 8 h.
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ntroduction
iving organisms possess wide assortments of elegant
anomachines, patterned arrays and highly structured
Open access under CC BY-NC-ND license.acromolecules performing diverse biological functions.
acromolecules of DNA, RNA and proteins have intrinsi-
ally deﬁned features at the nanometer scale and can serve
s powerful building blocks for the bottom-up fabrication
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Figure 1 Sequence and secondary structure of phi29 DNA-packaging RNA (pRNA). (A) Illustration of the phi29 packaging motor
geared by hexameric pRNA ring (cyan, orange, green, blue, brown, and purple structures). (B) Sequence of pRNA monomer Ab′. The
central domain for constructing the pRNA-X is boxed. (C) The core of the pRNA-X domain composed of four RNA oligos (a, b, c, and
d). Helical segments are represented as H1, H2, H3 and H4. The additional bases used to construct the pRNA-X motif in helices H2
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f biomimetic nanostructures and nanodevices [1,2]. RNA
s a particularly attractive candidate for such applications
3—8], since it can be designed and manipulated with a
evel of simplicity characteristic of DNA, while possessing
versatile ﬂexibility in structure and function similar to
ome properties of proteins [9]. Simple chemical modiﬁca-
ions such as, 2′-Fluoro (2′F) can generate RNAs resistant
o degradation without changing its folding into appropri-
te 3D structure, while retaining authentic biological and
nzymatic functions [10,11].
There are many types of RNA molecules that could
otentially be utilized for nanotechnology-based therapy
uch as small interfering RNAs [12—14], ribozymes [15—17],
NA aptamers [18,19], riboswitches [20,21], and miRNAs
22—24]. Although the methods for gene silencing with high
fﬁcacy and speciﬁcity have been achieved in vitro, the
ffective delivery of RNA to speciﬁc cells in vivo remains
hallenging. The development of a safe, efﬁcient, speciﬁc
nd nonpathogenic nanodevice for the delivery of multiple
herapeutic RNAs is in high demand. RNA nanotechnology
olds great potential in this regard: (1) Homogeneous RNA
anoparticles can be manufactured with high reproducibil-
ty and known stoichiometry, thus avoiding unpredictable
ide effects or nonspeciﬁc toxicity associated with hetero-
eneous structures. (2) Using the bottom up approach, RNA
anoparticles can be assembled harboring multiple thera-
eutic, reporter and/or targeting payloads for synergetic
ffects [12]. (3) Cell type-speciﬁc gene targeting can be
chieved via simultaneous delivery and detection modules
hich reduces off-target toxicity and lowers the concentra-
ion of the drug administered, thus reducing the side effects
f the therapeutics. (4) RNA nanoparticle size typically
anges from 10—50 nm, an optimal size for a non-viral vector
s they are large enough to be retained by the body yet small
nough to pass through the cell membrane via the cell sur-
ace receptors mediated endocytosis. The advantageous size
as the potential to greatly improve the pharmacokinetics,
harmacodynamics, biodistribution, and toxicology proﬁles
y avoiding non-speciﬁc cell penetration [25]. (5) Protein-
ree RNA nanoparticles with RNA aptamers as anti-receptors
h
o
t
t27].
an yield superior speciﬁcity compared to protein anti-
eceptors while displaying lower antibody-inducing activity.
his will provide an opportunity for repeated administration
nd treatment of chronic diseases. (6) RNA nanoparticles are
reated as chemical drugs rather than biological entities,
hich might facilitate FDA approval.
However, one of the challenges in this emerging
eld of RNA nanotechnology is the relative instability
f the nanoparticles without covalent modiﬁcations or
ross-linking, resulting in the dissociation at ultra low
oncentrations in vivo after systemic injection. This has
eriously hindered the delivery efﬁciency and therapeutic
pplications of RNA nanoparticles.
The feasibility of RNA nanotechnology in disease therapy
as been exempliﬁed in the phi29 pRNA therapeutic system
11—15,17,26]. The DNA packaging motor of bacteriophage
hi29 (Fig. 1A) is geared by a hexameric pRNA ring [27—29],
hich contains two functional domains [30,31]. The cen-
ral domain of each pRNA subunit contains two interlocking
oops, denoted as the right- and left-hand loops (Fig. 1B)
hat can be reengineered to form dimers or trimers via hand-
n-hand interactions [32—36]. The helical DNA packaging
omain is located at the 5′/3′ paired ends [31,37]. The two
omains are connected by a three-way junction (3WJ) region
11]. We have recently demonstrated that the 3WJ region
xtracted from the pRNA can be assembled from three
ieces of RNA oligos to construct trivalent RNA nanoparti-
les [11]. In this communication, we demonstrate that the
enterfold domain of the pRNA could be engineered to form
X-shaped motif (Fig. 1C), which was thermodynamically
table, resistant to denaturation by 8M urea and remained
ntact at ultra-low concentrations. Incubation of four RNA
ligos each carrying one of the four small RNA molecules,
iRNA, receptor binding aptamer, or folate resulted in the
ormation of tetravalent RNA nanoparticles as potential
herapeutic agents. We proved that each one of the four
elices in the X-motif can serve as a sticky-end to link
ne siRNA or other therapeutic molecules without affecting
he folding of the central pRNA-X core. Systemic injec-
ion of ligand-containing nanoparticles into the tail-vein
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Figure 2 Assembly and stability of the pRNA-X core. In the
table, ‘+’ indicates the presence of the RNA oligo in samples
of the corresponding lanes M: DNA ladder. (A) 15% native PAGE
and 8M denaturing PAGE gels showing the step-wise assembly of
the pRNA-X core. (B) Melting curves for the individual pRNA-X
strands (magenta, red, blue, and black) and the pRNA-X coreTetravalent RNA nanoparticles for targeting to cancers
of mice revealed that the RNA nanoparticles remained intact
and strongly bound to cancers without entering the liver,
lung or any other vital organs or tissues.
Results and discussion
Length and sequence requirements of the helical
stem regions of the pRNA for the assembly of the
X-motif
The pRNA-X motif was constructed by (1) opening the right-
hand loop of pRNA to insert 9 base pairs, thereby forming
a double helical segment (Helix H2), and (2) extending the
H3 helix by 4 base pairs (Fig. 1C). The length of the helices
H1, H3 and H4 were 8 base pairs, respectively, while H2
was 9 base pairs long. Although 6 base pairs are sufﬁcient
for the assembly of the junction domain, 8 base pairs are
necessary to keep the junction domain stable under strongly
denaturing conditions [11].
Thermodynamically stable properties displayed by
the pRNA X-motif
The pRNA-X motif was assembled by mixing four RNA oli-
gos, denoted a, b, c, and d in stoichiometric ratio at room
temperature. The afﬁnity and efﬁciency of assembly was
investigated by both gel shift assays and melting experi-
ments conducted under the physiological buffer TMS in the
presence of 5mM magnesium and 100mM sodium chloride at
pH 7.6. The gel-shift assays demonstrate that if one or two
strands are omitted (lanes 1—6), they have a faster migra-
tion rate compared to the pRNA-X-core (lane 7) (Fig. 2A,
top). The core remained stable in 8M urea (Fig. 2A, bot-
tom), thereby demonstrating its stable properties. Melting
experiments displayed a very smooth, high-slope tempera-
ture dependent melting curve indicating that the four oligos
of the pRNA-X core (TM of 62.7± 3.2 ◦C) have a higher afﬁn-
ity to interact favorably compared to any of the individual
component strands (Fig. 2B). The robust attributes of the
3WJ core have already been demonstrated using compe-
tition assays at different temperatures and in presence of
0—8M urea [11].
Self-assembly of stable RNA nanoparticles
harboring small RNA molecules linked to the
X-motif
Extension of the phi29 pRNA at the 3′-end does not affect the
folding of pRNA global structure [11,34]. Accordingly, the
sequences of the four RNA oligos a, b, c, and d were placed
at the 3′-end of the pRNA monomer, Ab′. Mixing of the four
resulting pRNA chimeras at equimolar concentrations led to
the assembly of X-shaped branched nanoparticles harboring
one pRNA at each branch. AFM images conﬁrmed the for-
mation of larger RNA complexes with four-branches (Fig. 3A
and B), which were consistent with gel shift assays com-
paring monomer (Ab′), dimer (Aa′), 3WJ-3pRNA [11] and
pRNA-X—4pRNA (Fig. 3C). The dimer (Aa′) formed via hand-
in hand interactions of interlocking loops is only stable up
to 2M urea, while the 3WJ—3pRNA and the pRNA-X—4pRNA
(green).
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Figure 3 Construction of tetravalent pRNA-X nanoparticles harboring monomeric pRNA at each branch. (A) Schematic of pRNA-
X—4pRNA constructs, (B) corresponding AFM images, (C) 8% native (left) and denaturing (right) PAGE gel, (D) dissociation assay for
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ihe pRNA-X—4pRNA constructs by 4-fold serial dilution with [32P
he lowest detectable concentration of 25 pM. Scale bar: 50 nm
re both stable in presence of 8M urea. The pRNA-X—4pRNA
anoparticles can also be co-transcribed and self-assembled
n one step during transcription with high yield.
As a candidate therapeutic RNA nanoparticle, the pRNA-
constructs with four branches harboring multi-module
unctionalities have to remain intact after systemic deliv-
ry, where it will exist at ultra low concentrations due
o dilution by circulating blood. To assay the dissocia-
ion, [-32P] labeled pRNA-X nanoparticles were serially
iluted to extremely low concentrations (100 nM to 1 pM).
he concentration for dissociation was below the detec-
ion limit of the [32P]-labeling technology; at 25 pM in
MS buffer, the lowest detectable concentration, the
RNA-X nanoparticles showed no signs of dissociation
Fig. 3D).
onstruction of a variety of therapeutic RNA
anoparticles using the X-motif as scaffoldetravalent RNA nanoparticles were constructed using
he pRNA-X motif as a scaffold by incorporating four
unctional modules: MG (malachite green dye, triphenyl-
ethane) aptamer, luciferase siRNA (siLuci), survivin
(
i
a
tNA-X—4pRNA (lanes 1—9) from 100 nM to 1 pM. Arrow indicates
iRNA (siSurv) and folate (FA) (Fig. 4A), denoted
pRNA-X/MG/FA/siLuci/siSurv] or corresponding scram-
le siRNA control. The presence of the functional moieties
id not interfere with the formation of the pRNA-X core
nd the tetravalent complex assembled with high afﬁnity
Fig. 4B). The puriﬁed constructs (lane 9, Fig. 4B) were
table in absence of magnesium and remained intact
nder strongly denaturing conditions, even after the
ncorporation of functionalities. In the next sections, we
valuated whether the incorporated RNA moieties in the
RNA-X nanoparticles retain their original folding and
unctionalities.
ssessment of MG ﬂuorescence
G binding aptamer [38] was used as model system for
tructure and function veriﬁcation. Free MG is not ﬂuores-
ent by itself, but emits ﬂuorescent light after binding to
he aptamer. Fused MG-binding aptamer retained its capac-
ty to bind MG, as revealed by its ﬂuorescence emission
Fig. 4C). The ﬂuorescence is comparable to optimized pos-
tive controls and therefore conﬁrming that the MG aptamer
ssembled from two strands of the pRNA-X after incorpora-
ion into the RNA nanoparticles.
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Figure 4 Construction of multi-module RNA nanoparticles harboring MG (malachite green) aptamer, folate, luciferase siRNA, and
survivin siRNA. (A) Schematic and sequences of the tetravalent pRNA-X constructs. (B) Step-wise assembly of RNA nanoparticles
using the pRNA-X as scaffold with functionalities assayed by 8% denaturing urea PAGE. In the table, ‘+’ indicates the presence of the
RNA strands in samples of the corresponding lanes. (C) Functional assay of the MG aptamer incorporated in pRNA-X nanoparticles.
MG ﬂuorescence was measured using excitation wavelengths 475 and 615-nm. (D) Target gene knock-down effects of survivin siRNA
showed by RT-PCR (GADPH is the endogenous control) on mRNA level and Western Blot assay (-actin bands served as loading
control) on protein level. (E) Dual-luciferase assay for target gene knock-down of luciferase gene. The relative ﬁreﬂy luciferase
activity reﬂects the level of luciferase gene expression and is obtained by normalizing ﬁreﬂy luciferase activity using the internal
control renilla luciferase activity. Error bars represent s.d. (N = 3).
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Figure 5 Binding and entry of tetravalent pRNA-X nanoparticles into targeted cells. (A) Flow cytometry revealed that [pRNA-
X/MG/FA/siLuci/si/Surv] nanoparticles bound and speciﬁcally entered cells. Positive and negative controls were Cy3—FA—DNA and
Cy3[pRNA-X/MG/NH2/siLuci/si/Surv] (without FA), respectively. (B) Confocal images showed targeting of folate receptor positive
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ight panel). Blue represents nuclei, 3.
argeted gene silencing assay in cancer cell model
wo pRNA-X nanoparticles were constructed for assaying
he gene silencing effects harboring: (1) folate and survivin
iRNA [pRNA-X/MG/FA/siLuci/si/Surv]; (2) folate and sur-
ivin siRNA scramble control [pRNA-X/MG/FA/siLuci/siSurv
cram]. After 48-h transfection, both reverse transcription-
CR (RT-PCR) assayed on mRNA level and western blot
ssayed on protein expression conﬁrmed reduced survivin
ene expression level of [pRNA-X/MG/FA/siLuci/si/Surv]
D
t
c
ggreen, 1) and ﬂuorescent RNA nanoparticles (red, 2) (magniﬁed,
anoparticles compared to the scramble control (Fig. 4D).
he mechanism of siRNA release from the pRNA nanoparti-
les is by Dicer processing, as established previously [14].
argeted gene silencing of luciferase
ual-luciferase reporter system was used to quantita-
ively measure the gene silencing effects of the pRNA-X
onstructs harboring the siRNA targeting ﬁreﬂy luciferase
ene [39] (Fig. 4A). The relative luciferase activity was
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Figure 6 Construction of tetravalent pRNA-X nanoparticles
harboring multiple siRNA for enhanced gene silencing effects.
(A) Sequences and notations of siRNA used in tetravalent con-
structs. Blue: siLuci-1 and 1′; red: siLuci-2 and 2′; green: siLuci-3
and 3′; orange: siLuci-4 and 4′; black: control siRNA [42]. (B)
and (C) Quantiﬁcation of Luciferase gene expression: Effects of
increasing number of different Luciferase siRNAs (siLuci-1, 2, 3
and 4) (A); and four identical siRNA constructs (siLuci-1, 2, 3 or
4) incorporated in the pRNA-X motif (B). RLU, relative luciferase
units; siLuci-1′, 2′ 3′ and 4′ represent reversed siRNA sequences
for siLuci-1, 2, 3 and 4, respectively. Error bars represent s.d.
Figure 7 Comparison of gene silencing effects for a single
vs. multiple siRNAs incorporated in the pRNA-X motif. (A—D)
Four identical siRNA (siLuci-1, A; siLuci-2, B; siLuci-3, C; siLuci-
4, D) compared with a single siRNA harbored at each pRNA-X
motif arm; RLU: relative luciferase units; siLuci-1′, 2′ 3′ and 4′
represent reversed siRNA sequences for siLuci-1, 2, 3 and 4,
respectively. Error bars represent s.d. (N = 3).(N = 3).
used to reﬂect the expression level of ﬁreﬂy luciferase
gene by normalizing the ﬁreﬂy luciferase activity with
the internal control, renilla luciferase activity. The results
indicated that [pRNA-X/MG/FA/siLuci/si/Surv] nanoparti-
cles displayed ∼70% decrease in ﬁreﬂy luciferase gene
expression (Fig. 4E).
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Figure 8 (A) and (B) siRNA and pRNA-X nanoparticles were
transfected into HT29 GFP-Luc cells with Lipofectamine 2000
(siRNA#1 and 2: 100 nM; pRNA-X: 1 nM). (C) Effect of pRNA trans-
fection on the cytotoxicity in HT29 cells. Growth inhibition was
measured after treatment of cells with pRNA for 24 h in 96-
well plates. Cell numbers were quantitated by staining with
sulforhodamine B and expressed relative to cells treated with52
ell binding and entry of pRNA-X nanoparticles
olate was incorporated in the pRNA-X nanoparticles to
erve as a cancer cell delivery agent via folate receptor-
ediated endocytosis [11,14,40]. Fluorescent pRNA-X
anoparticles with folate conjugated into one of the
ranches of the pRNA-X complex were tested for cell
inding efﬁciency. pRNA-X harboring FA and Cy3 labels
Cy3—pRNA-X/MG/FA/siLuci/si/Surv] served as the test
ample, while the negative control harbored NH2 and Cy3
abels [Cy3—pRNA-X/MG/NH2/siLuci/si/Surv]. Flow cytom-
try (Fig. 5A) and confocal imaging indicated a strong
inding of the RNA nanoparticles and efﬁcient entry
nto the targeted cells, as demonstrated by the excel-
ent co-localization and overlap of the ﬂuorescent pRNA-X
anoparticles (red) and cytoplasma (green) (Fig. 5B).
ene silencing effects were progressively
nhanced as the number of siRNA in each pRNA-X
anoparticles increased gradually from one, two
hree to four
etravalent pRNA-X complexes were constructed harboring
ultiple luciferase siRNAs to assay for enhanced gene silenc-
ng effects. Dual-luciferase reporter system was used to
uantitatively measure the gene silencing effects. For all
he constructs, the total concentration of RNA was kept con-
tant at 1.25 nM. The target sites on the luciferase gene for
he four siRNAs (Fig. 6A) were located at 153—173, 196—216,
98—518, and 846—869 positions, as published in the lit-
rature [41,42]. The incorporation of four identical siRNA
equences compromised the assembly of the X-motif due to
elf-folding of the complementary sequences of the respec-
ive siRNAs. To facilitate the assembly, the siRNA sequences
ere reversed (denoted with a prime, such as siLuci-1′) at
lternate helical branch locations. The reversed sequences
ad no impact on the functionality of the siRNA.
ilencing effects with increasing number of different
uciferase siRNA
s the number of different luciferase siRNAs were grad-
ally increased in the pRNA-X motif, progressive increase
n silencing effects were observed as follows, ∼25% (for
siRNA; 3 scramble siRNA), 57% (for 2 siRNA; 2 scramble
iRNA), 72% (for 3 siRNA; 1 scramble siRNA), and 81% (for 4
iRNA) (Fig. 6B).
ilencing effects of four identical luciferase siRNAs
igniﬁcant silencing effects were observed in presence of
our identical siRNAs fused to the pRNA-X motif, com-
ared to a single siRNA as follows, ∼74% (for four siLuci-1),
90% (for four siLuci-2), ∼80% (for four siLuci-3), and
72% (for four siLuci-4) (Fig. 6C). For comparison, we
onstructed the X-motif harboring a single siRNA (either
iLuci-1 or 2 or 3 or 4) at helical locations H1, H2, H3
r H4, respectively (Fig. 7A—D). The silencing effects of
he four different siRNAs increased following the trend,
iLuci-2 > siLuci-1≈ siLuci-4 > siLuci-3. The functionality of
he siRNA was comparable at each of the arms of the X-
otif. The data demonstrated that greatly enhanced effects
ere observed in presence of four identical siRNAs compared
o a single siRNA (Fig. 7A—D).
Lipofectamine alone. RLU, relative luciferase units. Error bars
represent s.d. (N = 3).
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Figure 9 In vivo binding and targeting of pRNA-X nanoparticles. (A) The pRNA-X (harboring Folate and Alexa-647) nanoparticles
upon
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Cspeciﬁcally targeted folate-receptor positive tumor xenografts
body imaging (A), and internal organ imaging (B). Control: PBS
Silencing effects of pRNA-X harboring four luciferase
siRNAs versus single standard siRNA
Fireﬂy luciferase reporter was chosen as knockdown tar-
get for in vitro pRNA-X treatment. Two siRNA sequences
(siLuci-1 and 2) were selected and tested in HT29 colon
cancer cells with stable luciferase expression. To demon-
strate that the pRNA-X system provides a superior delivery
vehicle for siRNA, a direct comparison of the in vitro knock-
down efﬁcacy compared to standard siRNA (siLuciferase-1
and 2) was carried out (Fig. 8A and B). A 1% concentration of
pRNA-X nanoparticles with four siRNA modules can achieve
the same silencing effects (∼60—70% decrease compared to
scramble controls) as the siRNA by itself. Absence of nonspe-
ciﬁc luciferase inhibition was conﬁrmed by sulforhodamine
B assay (Fig. 8C).
In vivo targeting of RNA nanoparticles to cancer
xenograft by systemic injection
To conﬁrm the chemical and thermodynamic stability of the
X-shaped RNA nanoparticles for speciﬁc cancer targeting
in vivo, RNA nanoparticles were constructed with one of the
four RNA fragments carrying the folate to serve as a ligand
for binding to the cancer cells, and another RNA fragment
carrying the ﬂuorescent dye Alexa-647. The nanoparticles
were systemically injected (i.e., tail vein injections) into
athymic nude mice bearing KB cells (folate receptor pos-
itive) xenografts in the subcutaneous ﬂanks. Whole body
imaging (at time points, 1-h, 4-h and 8-h) were carried out
after intravenous administration of FA—pRNA-X—Alexa647
nanoparticles. The pRNA-X nanoparticles strongly bound to
the tumor xenografts within 4-h (Fig. 9). The animals were
sacriﬁced at 8-h time point and organ imaging revealed that
ﬂuorescence was localized speciﬁcally in the tumor and was
not detected in other organs of the body, indicating that
the particles are not trapped in the liver, lungs, kidneys or
other tissues or organs after systemic injection (Fig. 9B). The
results were conﬁrmed to be reproducible by three indepen-
dent labs with ﬁve trials. Together, these ﬁndings suggest a
very selective targeting of the pRNA nanoparticles to tumors
and not to normal tissues which would make this delivery
system highly efﬁcacious for future clinical applications.
T
w
tsystemic administration in nude mice, as revealed by whole
ed mice. Scale bar: ﬂuorescent intensity.
onclusions
e demonstrated that the central domain of bacteriophage
hi29 motor pRNA can be engineered into a stable X-motif
o carry four functional modules in the absence of metal
ons. The resulting nanoparticles were thermodynamically
table, and resistant to dissociation under strongly dena-
uring conditions or at ultra-low concentrations. Incubation
f four RNA oligos representing therapeutic functional
otifs resulted in the self-assembly of tetravalent RNA
anoparticles as potential therapeutic agents. Progressive
nhancement of gene silencing effects were observed when
he number of siRNA in each pRNA-X nanoparticles increased
rom one to two, three and four. The results demonstrated
hat a wide range of therapeutic RNA molecules targeting
ancer and viral infected cells can potentially be fused to
he multivalent pRNA-X motif to achieve enhanced silencing
ffects.
xperimental procedures
n vitro synthesis and puriﬁcation of pRNA
he pRNA were synthesized by enzymatic methods as
escribed previously [31]. RNA oligos were synthesized
hemically by IDT (Iowa). RNAs were puriﬁed by 8M urea
% PAGE. The corresponding bands were excised under UV
hadow and eluted from the gel over 4 h at 37 ◦C in the
lution buffer (0.5M NH4OAc, 0.1mM EDTA, 0.1% SDS, and
.5mM MgCl2) followed by ethanol precipitation overnight
t −20 ◦C (2.5 volume of 100% ethanol and 1/10 volume of
M NaOAc). The precipitate was pelleted by centrifugation
16500× g, 30min), washed with 70% ethanol, and dried by
peed vacuum. Finally, the RNA dried pellet was rehydrated
n 0.05% DEPC treated water and stored at −20 ◦C.
onstruction of multi-module RNA nanoparticleshe sequences for each of the RNA strands a, b, c, and d
ere added to the 3′-end of each 117-nt pRNA-Ab′ and syn-
hesized using two primers: 3′-end primer encoding the a, b,
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, and d, respectively, and a common 5′-end primer and the
b′ template. The template was then used in transcription
ixture and the pRNA was then puriﬁed in 8% urea PAGE gel
n TBM buffer, as described previously [11].
The sequences for the luciferase siRNA, survivin siRNA,
alachite green (MG) binding aptamer and folate labeled
NA were rationally designed with the sequences of the
trands a, b, c, and d, respectively (Fig. 4). Multi-module
anoparticles pRNA-X/MG aptamer/Folate/luciferase siRNA
nd survivin siRNA, denoted [pRNA-X/MG/FA/siLuci/siSurv]
r scramble control, denoted [pRNA-X/MG/FA/siLuci/siSurv
cram] were assembled from ﬁve individual fragments
ncluding a 26-nt folate labeled RNA (Trilink) or folate-DNA
trand (synthesized in house). The individual RNA strands
fragments 1, 2, 3 and 4, Fig. 4A) were transcribed from DNA
emplate ampliﬁed by PCR. Fluorescent dyes were labeled
n one RNA strand by using the Label IT® siRNA Tracker Intra-
ellular Localization Kit, Cy3TM (Mirus Bio LLC). The ﬁve RNA
trands were mixed after puriﬁcation in TMS buffer at equal
olar ratio and then heated up to 80 ◦C for 5min, followed
y slow cooling to 4 ◦C. The assembled nanoparticles were
hen puriﬁed from 8% native PAGE gel.
ilution assay to test dissociation at extremely low
oncentrations
he stability of the tetravalent pRNA-X—4pRNA nanopar-
icles were evaluated by radiolabel assays. Puriﬁed [32P]
RNA-X—4pRNA complexes were serially diluted from 100 nM
o 1 pM in TMS buffer, and then loaded onto 8% native PAGE
el for autoradiograph.
elting experiments
he melting experiments were conducted by monitoring
he ﬂuorescence of the pRNA-X component strands using
he LightCycler® 480 Real-Time PCR System (Roche). 1×
YBR Green I dye (Invitrogen) (emission 465—510 nm), which
inds double-stranded nucleic acids, but not single-stranded
nes was used for all the experiments. The respective RNA
ligonucleotides were mixed at room temperature in phys-
ological TMS buffer. The pRNA-X core strands were slowly
ooled from 95 ◦C to 20 ◦C at the ramping rate of 0.11 ◦C/s.
ata was analyzed by the LightCycler® 480 Software using
he ﬁrst derivative of the melting proﬁle. The TM value rep-
esents themean and standard deviation from 4 independent
xperiments.
low cytometry analysis of folate mediated cell
inding
uman cervical cancer Hela cells [American Type Culture
ollection (ATCC)] were maintained in folate-free RPMI-
640 medium (Gibco), then trypsinized and rinsed with PBS
137mM NaCl, 2.7mM KCl, 100mM Na2HPO4, 2mM KH2PO4,
H 7.4). 200 nM Cy3 labeled pRNA-X complexes harboring
olate [Cy3—pRNA-X/MG/FA/siLuci/si/Surv], and folate-free
ontrol [Cy3—pRNA-X/MG/NH2/siLuci/si/Surv] were each
ncubated with 2× 105 KB cells at 37 ◦C for 1 h. After wash-
ng with PBS, the cells were resuspended in PBS buffer. FlowF. Haque et al.
ytometry (Beckman Coulter) was used to observe the cell
inding efﬁcacy of the Cy3—pRNA-X nanoparticles.
onfocal microscopy
ela cells were grown on glass coverslides in folate free
edium overnight. Cy3 labeled pRNA-X complexes harboring
olate [Cy3—pRNA-X/MG/FA/siLuci/si/Surv], and folate-free
ontrol [Cy3—pRNA-X/MG/NH2/siLuci/si/Surv] were each
ncubated with the cells at 37 ◦C for 2 h. After washing
ith PBS, the cells were ﬁxed by 4% paraformaldehyde
nd stained by Alexa Fluor® 488 phalloidin (Invitrogen) for
ytoskeleton and TO-PRO®-3 iodide (642/661) (Invitrogen)
or nucleus. The cells were then assayed for binding and cell
ntry by Zeiss LSM 510 laser scanning confocal microscope.
alachite green (MG) aptamer ﬂuorescence assay
he pRNA-X tetravalent RNA nanoparticles [pRNA-
/MG/FA/siLuci/si/Surv] harboring MG binding aptamer
100 nM) [38] was mixed with MG (2M) in binding buffer
ontaining 100mM KCl, 5mM MgCl2, and 10mM HEPES (pH
.4) and incubated at room temperature for 30min (Fig. 4C).
he ﬂuorescence was measured using a ﬂuorospectrometer
Horiba Jobin Yvon; SPEX Fluolog-3), excited at 475 nm
scanning from 540 to 800 nm for emission) and 615 nm
scanning from 625 to 800 nm for emission).
ssay for the silencing of genes in cancer cell
odel
wo pRNA-X nanoparticles were constructed for assaying
he gene silencing effects harboring: (1) folate and survivin
iRNA [pRNA-X/MG/FA/siLuci/si/Surv]; (2) folate and Sur-
ivin siRNA scramble control [pRNA-X/MG/FA/siLuci/siSurv
cram].
Hela cells were transfected with 25 nM of the individual
RNA-X complexes using Lipofectamine 2000 (Invitrogen).
fter 48-h treatment, cells were collected and target gene
ilencing effects were assessed by both RT-PCR and Western
lot assays.
Cells were processed for total RNA using illustra RNAspin
ini kits (GE Healthcare, Buckinghamshire, UK). The ﬁrst
omplementary DNA strand was synthesized on mRNA
500 ng) from Hela cells using SuperScript III First-Strand
ynthesis System (Invitrogen) according to manufacturer’s
nstruction. PCR was performed using GoTaq Flexi DNA
olymerase (Promega). Reactions were carried out in a
nal volume of 25L which contained complementary DNA
rom ﬁrst-strand synthesis (the cDNA template was 1:5,
:25 and 1:50 diluted respectively), 1× GoTaq Flexi color-
ess buffer, 2.5mmol/L Mg2+, 0.2mmol/L deoxynucleoside
riphosphates, 0.2mol/L of each primer, and 0.02U/L
oTaq Flexi DNA polymerase. The PCR condition was 95 ◦C
or 5min then 25 cycles of 94 ◦C for 1min, 55 ◦C for 1min
nd 72 ◦C for 1min, followed by 72 ◦C for 10min.
Primers for human GAPDH [43] and survivin [44] are:
GAPDH left: 5′-ACGGATTTGGTCGTATTGGGCG-3′;
GAPDH right: 5′-CTCCTGAAGATGGTGATGGAA-3′;
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Survivin left: 5′-GCATGGGTGCCCCGACGTTG-3′;
Survivin right: 5′-GCTCCGGCCAGAGGCCTCAA-3′.
Cells were rinsed and harvested in lysis buffer. Pro-
tein concentrations were determined and equal amounts of
proteins were loaded onto a 15% PAGE. Membranes were
blocked, incubated with primary antibody to survivin and
-actin (R&D Systems, Minneapolis, MN), and conjugated to
a secondary antibody (Sigma—Aldrich, St. Louis, MO). Mem-
branes were then blotted by ECL kit (Millipore, Billerica, MA)
and exposed to ﬁlm.
Assay for the silencing of genes in cancer cell
model
Dual-luciferase assays were used to test the potential
of the pRNA-X complex in escorting siRNA delivered into
cells. For dual-luciferase assays, Hela cells were seeded in
24-well plates. Gene silencing assays were performed by
co-transfecting [pRNA-X/MG/FA/siLuci/si/Surv] with both
plasmid pGL3 and pRL-TK (Promega, Madison, WI) coding for
ﬁreﬂy and renilla luciferase, respectively. The latter served
as an internal control to normalize the luciferase data (Dual-
Luciferase Reporter Assay System; Promega). Cells were
washed once with PBS and lysed with passive lysis buffer. The
plates were shaken for 15min at room temperature. 20L
of lysate were added to 100L of luciferase assay reagent
(LAR II) and ﬁreﬂy luciferase activity was measured. Upon
addition of 100L of Stop & Glo Reagent, control measure-
ments of renilla luciferase activity were then obtained. The
data was then normalized with respect to the renilla activity
for determining the average ratio of ﬁreﬂy to renilla activity
over several trials.
HT29 colon cancer cells, that express GFP and ﬁreﬂy
luciferase (HT29 GFP-Luc), were plated at 10,000 cells/well
in a 96-well black plate (Corning Life Sciences; Tewks-
bury, MA) overnight and then transfected with control
siRNA (NTC), siLuci#1, and siLuci#2 using Lipofectamine
(Invitrogen). The siRNAs and pRNA-X nanoparticles were
transfected into HT29 GFP-Luc cells at 100 nM and 1 nM
each, correspondingly. D-Luciferin potassium salt (Research
Products International Corp, Mount Prospect, IL) was dis-
solved in sterile PBS to make a stock solution of 10mg/mL;
the cell culture media was removed before addition of
100L of a 150g/mL solution of D-luciferin in PBS.
Plates were incubated at 37 ◦C for 5min before imaging.
The IVIS Spectrum system was used for in vitro imag-
ing of cells in 96-well plates. For quantiﬁcation of the
detected light, regions of interest were drawn by using Liv-
ing Image 3.1 software, and the photon counts per second
from each well were recorded and plotted. Cell numbers
were quantiﬁed by staining with sulforhodamine B assay
(Geno Technology, St. Louis, MO) as described previously
[45].AFM imaging
For all samples, specially modiﬁed mica surfaces (APS mica)
were used. The APS mica was obtained by incubation of
freshly cleaved mica in 167 nM 1-(3-aminopropyl)silatrane.
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he details of APS mica surface modiﬁcation is described
lsewhere [46,47]. The RNA samples were diluted with 1×
MS buffer to a ﬁnal concentration of 3—5 nM. Then, the
roplet of samples (5—10L) was immediately deposited
n APS mica. After 2min incubation on the surface, excess
amples were washed with DEPC treated water and dried
nder a ﬂow of Argon gas. AFM images in air were acquired
sing MultiMode AFM NanoScope IV system (Veeco/Digital
nstruments, Santa Barbara, CA) operating in tapping mode.
wo types of AFM probes were used for tapping mode imag-
ng in air: (1) regular tapping Mode Silicon Probes (Olympus
rom Asylum Research, Santa Barbara, CA) with a spring con-
tant of about 42N/m and a resonant frequency between
00 and 320 kHz. (2) Non-contact NSG01 DLC probes (K-Tek
anotechnology, Wilsonville, OR) with a spring constant of
bout 5.5N/m and a resonance frequency between 120 and
50 kHz.
nimal trial: in vivo targeting of tumor xenograft
y systemic injection of pRNA-X nanoparticles
ale athymic nudenu/nu (6—8 weeks old) mice were obtained
rom Taconic (Hudson, NY) and housed in clean, pathogen-
ree rooms in an environment with controlled temperature
27 ◦C), humidity, and a 12 h light/dark cycle. All animal
xperiments were approved by the Institutional Animal Care
nd Use Committee at University of Kentucky and were
onducted in accordance with guidelines issued by the
ational Institutes of Health for the care of laboratory ani-
als. Mice were fed a folate-free diet (Harlan Laboratories;
ndianapolis, IN) for a total of 2 weeks before the exper-
ment and injected with KB cells (3× 106 cells per mouse
n 100L PBS) subcutaneously. When the tumors grew to
bout 500mm3, the mice were anesthetized using isoﬂu-
ane gas (2% in oxygen at 0.6 L/min ﬂow rate) and injected
ntravenously through the tail vein with a single dose of
g of pRNA per gram of body weight of 2′-F U/C modiﬁed
olate-Alexa647-labeled pRNA-X nanoparticle in 300L of
BS. Whole-body imaging (Ex-Max 650 nm/Em-Max 668 nm)
as carried out at 1-h, 4-h and 8-h after pRNA administration
n IVIS Spectrum station (Caliper Life Sciences; Hopkin-
on, MA). Composite images obtained were comprised of
lack and white digital photos with an overlay of images
eﬂecting ﬂuorescent activity. The density map, measured
s photons/second/cm2/steradian (p/s/cm2/sr), were cre-
ted using the Living Image 3.1 (Caliper Life Sciences;
opkinton, MA) software and represented as a color gradient
entered at the maximal spot. Following CO2 asphyxiation
t 8-h after pRNA administration, the tumors, liver, heart,
ung and kidney of the mice were dissected and individually
maged.
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